WO2006054298A3 - Glycogen synthase kinase-3 inhibitors - Google Patents

Glycogen synthase kinase-3 inhibitors Download PDF

Info

Publication number
WO2006054298A3
WO2006054298A3 PCT/IL2005/001218 IL2005001218W WO2006054298A3 WO 2006054298 A3 WO2006054298 A3 WO 2006054298A3 IL 2005001218 W IL2005001218 W IL 2005001218W WO 2006054298 A3 WO2006054298 A3 WO 2006054298A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
gsk
glycogen synthase
synthase kinase
same
Prior art date
Application number
PCT/IL2005/001218
Other languages
French (fr)
Other versions
WO2006054298A2 (en
Inventor
Hagit Eldar-Finkelman
Moshe Portnoy
Original Assignee
L P Tel Aviv University Future
Hagit Eldar-Finkelman
Moshe Portnoy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L P Tel Aviv University Future, Hagit Eldar-Finkelman, Moshe Portnoy filed Critical L P Tel Aviv University Future
Priority to EP05809234A priority Critical patent/EP1824468A2/en
Priority to CA002587732A priority patent/CA2587732A1/en
Priority to CN2005800452120A priority patent/CN101098686B/en
Priority to JP2007542503A priority patent/JP4954888B2/en
Publication of WO2006054298A2 publication Critical patent/WO2006054298A2/en
Publication of WO2006054298A3 publication Critical patent/WO2006054298A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.
PCT/IL2005/001218 2004-11-18 2005-11-20 Glycogen synthase kinase-3 inhibitors WO2006054298A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05809234A EP1824468A2 (en) 2004-11-18 2005-11-20 Glycogen synthase kinase-3 inhibitors
CA002587732A CA2587732A1 (en) 2004-11-18 2005-11-20 Glycogen synthase kinase-3 inhibitors
CN2005800452120A CN101098686B (en) 2004-11-18 2005-11-20 Glycogen synthase kinase-3 inhibitors
JP2007542503A JP4954888B2 (en) 2004-11-18 2005-11-20 Glycogen synthase kinase-3 inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62854204P 2004-11-18 2004-11-18
US60/628,542 2004-11-18

Publications (2)

Publication Number Publication Date
WO2006054298A2 WO2006054298A2 (en) 2006-05-26
WO2006054298A3 true WO2006054298A3 (en) 2006-06-29

Family

ID=35655492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/001218 WO2006054298A2 (en) 2004-11-18 2005-11-20 Glycogen synthase kinase-3 inhibitors

Country Status (7)

Country Link
EP (1) EP1824468A2 (en)
JP (1) JP4954888B2 (en)
KR (1) KR20070086075A (en)
CN (1) CN101098686B (en)
AU (1) AU2005234687A1 (en)
CA (1) CA2587732A1 (en)
WO (1) WO2006054298A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (en) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1569956B1 (en) 2002-12-12 2014-02-26 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
GB0714941D0 (en) * 2007-08-01 2007-09-12 Imp Innovations Ltd Inhibitors
KR101592871B1 (en) * 2013-03-19 2016-02-11 부산대학교 산학협력단 Akt-activated Glycogen Synthetase Kinase Beta Inhibitory Peptide
CN105884827B (en) * 2015-02-13 2018-03-13 山东轩竹医药科技有限公司 Pyrimidine amide derivatives and its salt

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (en) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
WO2004052404A2 (en) * 2002-12-12 2004-06-24 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
WO2005000192A2 (en) * 2003-06-27 2005-01-06 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (en) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
WO2004052404A2 (en) * 2002-12-12 2004-06-24 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
WO2005000192A2 (en) * 2003-06-27 2005-01-06 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors

Also Published As

Publication number Publication date
EP1824468A2 (en) 2007-08-29
JP2008520649A (en) 2008-06-19
CN101098686B (en) 2012-03-14
JP4954888B2 (en) 2012-06-20
CN101098686A (en) 2008-01-02
AU2005234687A1 (en) 2005-12-08
CA2587732A1 (en) 2006-05-26
KR20070086075A (en) 2007-08-27
WO2006054298A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
WO2006083869A3 (en) Tumor necrosis factor inhibitors
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2008089310A3 (en) Delta 5 desaturase inhibitors for the treatment of obesity
WO2005110477A3 (en) Combination therapies for cancer and proliferative angiopathies
WO2007087250A3 (en) Tricyclic inhibitors of 5-lipoxygenase
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2008115263A3 (en) Raf kinase inhibitors containing a zinc binding moiety
WO2008033562A3 (en) Kinase inhibitor compounds
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2008121687A3 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2008098104A8 (en) Inhibitors of akt activity
WO2007079164A3 (en) Protein kinase inhibitors
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2008156614A3 (en) Imidazopyrazines as protein kinase inhibitors
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2005118824A3 (en) Methods and compositions for the inhibition of gene expression
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007137066A3 (en) HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2587732

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007542503

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077013214

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005809234

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2618/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580045212.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005809234

Country of ref document: EP